Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

IDH2 (isocitrate dehydrogenase 2) mutant inhibitor and application thereof

A technology of solvents and compounds, applied in the field of medicine, can solve problems such as cell metabolism disorders

Active Publication Date: 2017-06-09
JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Another view is that the structure of 2-HG is similar to that of α-KG, and it can competitively inhibit the targets of α-KG, such as histone demethylase, TET1 / 2 hydroxymethyl The methylation of DNA and histone directly affects the expression and differentiation of mRNA, leading to the disorder of cell metabolism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • IDH2 (isocitrate dehydrogenase 2) mutant inhibitor and application thereof
  • IDH2 (isocitrate dehydrogenase 2) mutant inhibitor and application thereof
  • IDH2 (isocitrate dehydrogenase 2) mutant inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1: Compounds against IDH 2 / R140Q inhibitory activity assay

[0071] IDH 2 The / R140Q mutant can catalyze the conversion of α-KG to 2-HG and simultaneously oxidize NADPH to NADP+ . Therefore, the inhibitory activity of the compound on the IDH2 / R140Q mutant can be determined by detecting the consumption value of NADPH.

[0072] The detailed method is: add the reaction solution containing 25mM Tris (pH7.4), 150mM NaCl, 10mM MgCl2, 0.03% BSA in a 96-well plate, add 100ng / mL IDH 2 / R140Q and different concentrations of compounds were incubated at 30°C for 1 hour, then 1 mMα-KG and 10 μM NADPH were added, the total system was 200 μL, and the absorbance value of NADPH was continuously detected within 16 hours using a Thermo microplate reader at 30°C and 340 nM wavelength. The final concentration gradient of the compound was set to (10000, 5000, 1000, 500, 100, 50, 10, 5, 1, 0.5, 0.1, 0.01) nM, and the inhibitory activity IC of the compound on IDH2 / R140Q was calcula...

Embodiment 2

[0073] Example 2: Compounds against IDH 2 / R172K inhibitory activity assay

[0074] IDH2 / R172K mutant can catalyze the conversion of α-KG to 2-HG and simultaneously oxidize NADPH to NADP + . Therefore, the inhibitory activity of the compound on the IDH2 / R172K mutant can be determined by detecting the consumption value of NADPH.

[0075] Detailed measurement method with reference to embodiment 1.

Embodiment 3

[0076] Example 3: Compounds against wild-type IDH 2 Inhibitory Activity Determination of

[0077] Wild-type IDH2 in NADP + Under the auxiliary effect, the isocitrate ICT is catalyzed into α-KG, accompanied by the generation of NADPH. Therefore, the inhibitory activity of the compound on IDH2 can be determined by detecting the increase of NADPH.

[0078] The detailed method is as follows: add a reaction solution containing 50mM Tris (pH7.4), 5mM MgCl2, 0.03% BSA to a 96-well plate, add 100ng / mL IDH2 and compounds of different concentrations, incubate at 30°C for 1 hour, and then add 200μM ICT and 200 μM NADP + , the total system was 200 μL, and the change in the absorbance value of NADPH within 16 hours was continuously detected at 30° C. and 340 nM wavelength using a Thermo microplate reader. The final concentration gradient of the compound was set to (10000, 5000, 1000, 500, 100, 50, 10, 5, 1, 0.5, 0.1, 0.01) nM, and the inhibitory activity IC of the compound on IDH2 was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound of formula I shown in the description and its pharmaceutically salts, solvents and hydrates, as well as a pharmaceutical composition comprising the compound of formula I and application thereof as an IDH (isocitrate dehydrogenase 2) mutant inhibitor in the preparation of drugs for treating IDH mutation related diseases.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an IDH mutant inhibitor and its application in preparing medicine. Background technique [0002] One of the important features of cancer is the alteration of the cell's intrinsic metabolism, and the tricarboxylic acid cycle is an important pathway that affects metabolism. It has been found that there are three enzyme mutations in the tricarboxylic acid cycle that are closely related to cancer. They are succinate dehydrogenase, fumarate hydratase, and recently discovered isocitrate dehydrogenase (Isocitrate dehydrogenase, IDH). The IDHs expressed in human cells are divided into three categories: IDH1 in the cytoplasm and IDH2 and IDH3 in the mitochondria. Cancer-related mutations mainly occur in IDH1 and IDH2. Acute myeloid leukemia (AML) is a malignant tumor disease with abnormal proliferation of myeloid leukocytes, which is highly heterogeneous, and its incidence gradually i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D295/135C07D307/52C07C319/20C07C323/44C07C315/04C07C317/42C07C273/18C07C275/40C07C275/42C07D317/66C07D213/71C07D213/75C07D409/12C07D335/02C07D309/04C07D295/155C07D209/08C07D333/24C07D333/32C07D333/20C07D307/14C07D239/42C07D307/16A61K31/402A61K31/4025A61K31/381A61K31/505A61K31/341A61K31/5375A61K31/277A61K31/404A61K31/4155A61K31/495A61K31/36A61K31/17A61K31/351A61K31/382A61K31/44A61K31/4436A61P35/00A61P35/02
CPCC07C273/18C07C275/40C07C275/42C07C315/04C07C317/42C07C319/20C07C323/44C07D209/08C07D213/71C07D213/75C07D239/42C07D295/135C07D295/155C07D307/14C07D307/16C07D307/52C07D309/04C07D317/66C07D333/20C07D333/24C07D333/32C07D335/02C07D409/12
Inventor 曹鹏陈姣杨杰
Owner JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com